Who
Laurence Reid
Director
Company insider
Files Form 4 as: Director, Metagenomi Therapeutics; Director, KalVista Pharmaceuticals; President and Chief Executive, Decibel Therapeutics; SVP, Chief Business Officer, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 72
- Buys
- 3
- Sells
- 7
- Bought
- $133K
- Sold
- $5.2M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Jun 2010
- Last trade
- 9 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 11 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K19,883 at $1.17 | filing |
| 9 Sep 2026filed 11 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Bought | $138117 at $1.18 | filing |
| 9 Sep 2026filed 11 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Bought | $23K19,883 at $1.17 | filing |
| 9 Sep 2026filed 11 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Bought | $138117 at $1.18 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —17,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,000 | filing |
| 9 Jun 2026filed 11 Jun 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,400 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,400 at $0.00 | filing |
| 2 Sep 2025filed 2 Sep 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 23 Nov 2024filed 26 Nov 2024 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 25 Sep 2023filed 25 Sep 2023 | Decibel Therapeuticsoption or derivative | SEC FORM 4 Code D | —187,500 | filing |
| 25 Sep 2023filed 25 Sep 2023 | Decibel Therapeuticsoption or derivative | SEC FORM 4 Code D | —72,000 | filing |
| 25 Sep 2023filed 25 Sep 2023 | Decibel Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,072,539 | filing |
| 25 Sep 2023filed 25 Sep 2023 | Decibel Therapeutics | SEC FORM 4 Code D | —220,849 | filing |
| 16 Mar 2023filed 17 Mar 2023 | Decibel Therapeuticsoption or derivative | SEC FORM 4 Code A | —72,000 at $0.00 | filing |
| 16 Mar 2023filed 17 Mar 2023 | Decibel Therapeutics | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 25 Feb 2022filed 28 Feb 2022 | Decibel Therapeuticsoption or derivative | SEC FORM 4 Code A | —187,500 at $0.00 | filing |
| 15 Sep 2021filed 17 Sep 2021 | Decibel Therapeutics | SEC FORM 4 Bought | $76K10,000 at $7.64 | filing |
| 31 Dec 2014filed 5 Jan 2015 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $272K17,000 at $15.99 | filing |
| 31 Dec 2014filed 5 Jan 2015 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $272K2,802 at $97.00 | filing |
News
Metagenomi (NASDAQ:MGX) Director Laurence Reid Acquires 20,000 Shares of Stocktickerreport.com · 12 Sep 2026
1 headline in the last 90 days name Laurence Reid; 0 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.